CANbridge Pharmaceuticals Inc.

SEHK:1228 Stock Report

Market Cap: HK$71.8m

CANbridge Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for CANbridge Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

Nov 14
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Sep 27
CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Aug 07
Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23
CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CANbridge Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1228 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024105-408-254-217N/A
3/31/2024104-393-286-247N/A
12/31/2023103-379-319-278N/A
9/30/202395-416-316-291N/A
6/30/202387-453-314-304N/A
3/31/202383-468-305-292N/A
12/31/202279-483-296-281N/A
9/30/202266-733-340-327N/A
6/30/202254-982-384-373N/A
3/31/202242-1,089-599-591N/A
12/31/202131-1,077-461-587N/A
9/30/202127-1,055-391-515N/A
6/30/202122-1,034-321-443N/A
3/31/202118-828-218-196N/A
12/31/202012-846-305-152N/A
12/31/20191-218-169-126N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1228's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1228's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1228's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1228's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1228's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1228's Return on Equity is forecast to be high in 3 years time


Discover growth companies